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recent years, there has been considerable research focused on effective dietary interventions that may 
prevent or ameliorate ARCD and dementia. While a number of studies have considered the impact that 
dairy products may have on physiological health, particularly with regard to the metabolic syndrome and 
cardiovascular health, further research is currently needed in order to establish the impact that dairy 
products have in the promotion of healthy brain function during ageing. The present review considers the 
available evidence for the positive effects of dairy products on the metabolic syndrome and glucose 
regulation, with consideration of the implications for neurocognitive health. A literature search of current 
(September 2010) meta-analyses/reviews and original research regarding dairy products and cognition 
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cheese, yoghurt, probiotics, whey protein, alpha lactalbumin, calcium, B-12, bioactive peptides and 
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syndrome, diabetes, insulin resistance and glucose regulation. Concerns regarding SFA and other fatty 
acids found in dairy products are also reviewed in relation to different forms of dairy products. The review 
also considers recent evidence for positive neurocognitive effects associated with bioactive peptides, 
CLN and proline-rich polypeptides, α-lactalbumin, vitamin B12, calcium and probiotics. Future directions 
for the extraction and purification of beneficial constituents are also discussed. It is concluded that low-
fat dairy products, when consumed regularly as part of a balanced diet, may have a number of beneficial 
outcomes for neurocognitive health during ageing. 
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Abstract
Age-related cognitive decline (ARCD) and dementia are of increasing concern to an ageing population. In recent years, there has been
considerable research focused on effective dietary interventions that may prevent or ameliorate ARCD and dementia. While a number
of studies have considered the impact that dairy products may have on physiological health, particularly with regard to the metabolic syn-
drome and cardiovascular health, further research is currently needed in order to establish the impact that dairy products have in the pro-
motion of healthy brain function during ageing. The present review considers the available evidence for the positive effects of dairy
products on the metabolic syndrome and glucose regulation, with consideration of the implications for neurocognitive health. A literature
search of current (September 2010) meta-analyses/reviews and original research regarding dairy products and cognition was conducted
through SCOPUS using the following search terms for dairy consituents: dairy, milk, cheese, yoghurt, probiotics, whey protein, alpha lac-
talbumin, calcium, B-12, bioactive peptides and colostrinin (CLN). These search terms for dairy products were combined with the following
search terms related to cognition and health: cognition, cognitive decline, dementia, Alzheimer’s disease, metabolic syndrome, diabetes,
insulin resistance and glucose regulation. Concerns regarding SFA and other fatty acids found in dairy products are also reviewed in
relation to different forms of dairy products. The review also considers recent evidence for positive neurocognitive effects associated
with bioactive peptides, CLN and proline-rich polypeptides, a-lactalbumin, vitamin B12, calcium and probiotics. Future directions for
the extraction and purification of beneficial constituents are also discussed. It is concluded that low-fat dairy products, when consumed
regularly as part of a balanced diet, may have a number of beneficial outcomes for neurocognitive health during ageing.
Key words: Dairy products: Ageing: Dementia: Cognitive decline: Metabolic syndrome: Bioactive peptides
The world’s population is ageing rapidly, with 21 % of the
population (264 million people) estimated to be 60 years or
older in 2009. This estimate is projected to increase to 33 %
(416 million) by the year 2050(1). The impact of age-related
cognitive decline (ARCD) is a major societal health concern,
with up to 50 % of adults aged 64 years and over reporting
difficulties with their memory(2). In addition to normal cogni-
tive decline with ageing, over 20 million people worldwide
are also living with dementia, an estimate that is predicted
to reach 80 million by the year 2040(3). Alzheimer’s disease
(AD) is the most common form of dementia, affecting about
10 % of the population over the age of 65 years in the
USA(4). In response to the reality of an ageing population,
there has been increased research focus, in recent years, on
the development of effective dietary interventions that may
be preventative against the onset of dementia and help to
ameliorate age-related declines in cognitive ability.
Age-related deficits in cognitive abilities have been consist-
ently reported across a range of cognitive domains, including
processing speed, attention, episodic memory, spatial ability
and executive function(5–13). Longitudinal and cross-sectional
brain imaging studies have revealed that ARCD is correlated
most strongly with cortical volume decreases in the frontos-
triatal system(14–18), with decreases in prefrontal cortex
volume estimated to occur at a rate of approximately 5 %/
decade after the age of 20 years(16,17). Age-related reductions
in grey matter are due to a number of factors in addition to
neuronal loss, including shrinkage of neurons, reduction of
synaptic spines and lowered numbers of synapses. In contrast,
age-related reductions in white matter may be attributed in
*Corresponding author: Dr D. A. Camfield, fax þ61 3 9214 5230; email dcamfield@swin.edu.au; david.camfield@gmail.com
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part to large reductions in the length of myelinated axons,
by as much as 50 %(19). Current understanding of ARCD
points to multiple aetiological factors in the brain. These
include depletion of endogenous antioxidants(20), elevation
in NO(21) and homocysteine (HCy) levels(22), chronic inflam-
mation(23), glutamatergic excitotoxicity(24), accumulation of
redox metals(25), mitochondrial dysregulation(26) and Ca
dysregulation(27), as well as abnormal insulin levels and/or
responsiveness(28).
In the case of AD, additional pathological changes occur
in the brain, comprising the formation of extracellular senile
plaques from b-amyloid (Ab) proteins and intracellular neuro-
fibrillary tangles from t proteins, resulting in widespread
damage to neural structures and profound impairment to
cognitive abilities(29–31). The current Food and Drug Adminis-
tration-approved pharmaceutical treatments for dementia are
the cholinesterase inhibitors tacrine, donepezil, rivastigmine
and galantamine, as well as the N-methyl-D-aspartate receptor
antagonist memantine(32,33). Despite the recent UK National
Institute for Clinical Excellence recommendation to reverse
its previous decision and allow these drugs for mild as well
as moderate AD, the cholinesterase inhibitors are not always
well tolerated, with all four having adverse effects related to
cholinergic hyperactivity including nausea, vomiting, diar-
rhoea, fatigue, muscle cramps and dizziness. There are also
few data to support the notion of cholinesterase inhibitors
providing any more than symptomatic relief by increasing
dwindling levels of acetylcholine as the disease progresses(34).
Furthermore, few studies have been conducted that assess
the efficacy of cholinesterase inhibitors for longer than 1
year duration or answer the question as to whether they can
significantly delay the progression from mild cognitive
impairment to AD(35).
In consideration of the diverse aetiology of ARCD and
dementia, together with the limitations of current pharmaceu-
tical treatments, attention has turned to consideration of
dietary constituents for their potential to simultaneously
target multiple mechanisms and play a prophylactic role(36).
Epidemiological and prospective cohort studies have ident-
ified a number of dietary constituents that are associated
with a reduction in ARCD and a lowered risk of dementia.
The Mediterranean diet, with a high intake of MUFA from
olive oil, high consumption of fish and whole-grain cereals
and a moderate intake of red wine, has been found to be
protective against ARCD in a number of studies(37,38). Other
dietary constituents that have been found to be protective
against ARCD are antioxidants, including vitamins E and C,
fruit and vegetables and the B vitamins (B6, B12 and folate)
(39).
Until recently, the efficacy of dairy products in ameliorating
ARCD has received comparatively less research focus.
However, a growing body of epidemiological research now
links dairy consumption to a number of beneficial health out-
comes, including lowered risk of the metabolic syndrome,
heart disease and stroke(40). In light of the considerable
inter-relationship between CVD, the metabolic syndrome
and brain function(41), it is timely to assess the impact that
dairy constituents have on neurocognitive health. The objec-
tive of the present study is to review the evidence linking
different forms of dairy products with amelioration of ARCD,
when used regularly as part of the diet over the lifespan.
The review also presents current theories regarding likely
mechanisms of action by which the main constituents of
dairy products may have an impact on neurocognitive health.
Dairy products and general health
A number of epidemiological studies have provided evidence
to suggest that consumption of dairy products, in particular
low-fat dairy products, may be associated with a number of
beneficial health outcomes. These benefits include a decrease
in systolic blood pressure(42–45), a decrease in incidence of
type 2 diabetes and insulin resistance(46–48), as well as a
decreased risk of stroke and heart disease(47–49). Low-fat
dairy product intake has also been found to be associated
with decreased levels of inflammatory markers(50,51) as well
as with a reduced risk of colorectal cancer(47,52,53). In a
65-year follow-up study of the Boyd Orr cohort, a childhood
diet that was high in dairy products was not found to be
associated with a greater risk of heart disease or stroke, and
Ca intake during childhood was found to be inversely associ-
ated with stroke mortality(49). A prospective Japanese study
has also provided evidence to suggest that milk intake is
inversely associated with the risk of developing vascular
dementia(54). Conversely, some studies have suggested the
possibility of an increased risk of prostrate cancer associated
with high dairy product consumption, although the evidence
is inconsistent(52,55). While much of this evidence has been
obtained from epidemiological and prospective cohort studies
rather than from randomised controlled clinical trials, it is
nonetheless encouraging evidence in support of low-fat
dairy products being of positive health benefit.
Concerns over fatty acid content in dairy products
There is now a general consensus that dietary intake of SFA
represents a significant risk factor for CVD, due to elevation
of serum LDL-cholesterol(56). Dairy products have been
found to be the primary source of dietary SFA(57), with an esti-
mated 40 % of all SFA obtained through milk and dairy
products in the UK(58); and for this reason, there has been
concern that the consumption of dairy products may increase
the risk of CVD(59). However, an important distinction needs
to be made between milk and other forms of dairy products.
The proportion of SFA and other fatty acids in cheese and
butter is substantially higher than that found in milk(60).
Table 1 lists the fatty acid composition of milk, butter and
cheese from a selection of European countries. Here, it can
be seen that, while the proportions of fatty acids are roughly
equivalent between the three forms of dairy product, the over-
all total fat content (g/100 g) of butter and cheese is much
higher. The epidemiological evidence suggests that it is the
ratio of high-fat:low-fat dairy products that is associated
with a greater risk of CHD, not dairy consumption per se (61).
Nevertheless, in consideration of the widespread consumption
of bovine milk, investigations have begun into developing
D. A. Camfield et al.160
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techniques to reduce the SFA content and increase the
cis-MUFA content of milk(62).
It is also important to note that certain fatty acids found in
milk may not represent as much of a risk factor for CVD as
originally thought. There is evidence to suggest that lauric
acid (12 : 0) and myristic acid (14 : 0) increase the levels of
protective HDL-cholesterol, in addition to LDL-cholesterol,
thereby helping to reduce the ratio of total cholesterol:HDL-
cholesterol(63,64). However, palmitic acid (16 : 0) has been
found to have a less favourable effect on ratios of total choles-
terol to HDL-cholesterol(62). In addition to SFA, dairy products
also contain a number of other fatty acids. cis-MUFA is a fatty
acid which has been found to be beneficial in reducing the
risk of CVD(65), and dairy products have been found to
supply up to 30 % of dietary intake of cis-MUFA in some
European countries(58). Trans-fatty acids, which are generally
associated with a substantially increased CVD risk(66), are
also found in dairy products. It has been estimated that, on
average, dairy products contribute 38 % of total trans-fatty
acids across European countries(58). It is worth noting that
the isomeric forms of trans-fatty acids found in dairy products
do not appear to be as detrimental to cardiovascular health as
the trans-fatty acid isomers that are derived from industrial
hydrogenation of vegetable oils(67).
Dairy and the metabolic syndrome
The cluster of disorders including dyslipidaemia (high fasting
TAG levels combined with low HDL-cholesterol levels), hyper-
tension, obesity and glucose intolerance has become grouped
together under the umbrella term metabolic syndrome(68).
A diet with a low glycaemic index that is high in whole-grain
cereal and has a high unsaturated fatty acids:SFA ratio has
been found to be associated with a lower prevalence of the
metabolic syndrome(69–71). Due to the fatty acid content of
milk fat, it was originally suspected that milk consumption
would have a negative impact on the metabolic syndrome;
however, several studies have subsequently revealed that
consumption of milk and other dairy products is inversely
correlated with the metabolic syndrome(69,72,73). Various
constituents of dairy products that have a beneficial effect
on the metabolic syndrome have been identified; for example,
whey protein has been found to be insulinotropic(74), milk
peptides and Ca have been found to reduce blood press-
ure(75,76) and milk peptides and Ca may also help reduce
plasma cholesterol(77). Ca has been found to have a particu-
larly beneficial effect on serum lipid profiles, with evidence
from a number of studies demonstrating that Ca increases
HDL-cholesterol while decreasing both total cholesterol and
LDL-cholesterol(73). A possible mechanism by which Ca may
affect lipoprotein metabolism is through the inhibition of fat
absorption in the small intestine(78).
There is increasing evidence of a link between the meta-
bolic syndrome and both cognitive decline and dementia, par-
ticularly in individuals with high levels of inflammation(79,80).
Epidemiological evidence links many of the components of
the metabolic syndrome to increased ARCD and dementia,
including hypertension(81,82), diabetes(83,84), dyslipidae-
mia(85,86) and obesity(87). There are a number of mechanisms
that may potentially link the metabolic syndrome to cognitive
decline. These mechanisms include micro- and macrovascular
disease(88), inflammation and atherosclerosis(89), as well as the
secretion of inflammatory factors from adipose tissue(90,91).
However, perhaps the most important mechanism linking
the metabolic syndrome to cognitive decline is that of glucose
regulation(28,92–94).
Glucose regulation and brain function
In healthy, non-diabetic subjects, blood glucose levels peak at
approximately 1 h after the start of a meal and then return to
baseline levels within 2–3 h(95,96). Within 10 min of food
intake, there is a large release of endogenous insulin known
as the first-phase insulin response. However, for individuals
with increased insulin resistance or type 2 diabetes, the first-
phase insulin response is either absent or significantly
reduced, resulting in chronically elevated glucose levels
throughout the day(97). As a result of prolonged hyperglycae-
mia, insulin levels also remain high, and with continued
elevation of insulin levels, insulin resistance develops(98).
Those with good glucose tolerance, that is those whose
blood glucose returns to baseline quickly following a meal,
have been shown to demonstrate better memory than those
whose blood glucose levels remain elevated for longer
periods of time(99). Also in healthy young adults, poor
gluco-regulation, and thus a greater increase in blood glucose
after a glucose drink, has been associated with poorer per-
formance on tests of memory(100,101), vigilance(101,102), plan-
ning(101) and dichotic listening(103). Preclinical evidence
suggests that feeding young rats with high levels of saturated
fats leads to impaired glucose tolerance and reduced insulin
sensitivity(104–106), resulting in memory impairment(107,108).
One experiment(109) examined the impact of gluco-regulation
on a variable interval-delayed alternation task, a task that is
associated with hippocampal function. Rats fed high-fat diets
produced performance deficits, suggesting that impaired glu-
cose regulation moderated hippocampal-dependent memory.
However, these deficits were reversed by a 100 mg/kg glucose
injection(109). Interestingly, there was no effect of glucose in
Table 1. Fatty acid composition of milk, butter and cheese across
European countries*†
(Mean values and percentages of methyl esters)
Milk Butter Cheese
Fatty acid class Mean % Mean % Mean %
18 : 1 t 2·60 0·64 2·91 0·52 2·69 0·57
Total trans 4·26 0·62 4·79 0·75 4·49 0·67
18 : 0 11·01 0·91 11·07 0·91 11·23 1·22
Total SFA‡ 64·74 2·80 63·92 2·07 64·91 2·21
Total cis 26·94 1·97 27·40 1·99 26·64 1·53
Unidentified 3·33 0·74 3·39 0·44 3·22 0·43
Total fat (g/100 g) 3·33 0·78 82·32 3·32 27·27 6·65
* Countries included are Belgium, Denmark, Finland, France, Germany, Greece,
Iceland, Italy, The Netherlands, Norway, Portugal, Spain, Sweden and the UK.
† Adapted from Aro et al.(60).
‡ Excluding less than eight-carbon fatty acids.
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animals that received a normal diet, suggesting that glucose
was only effective in cases where there was a pre-existing
deficit in glucose regulation.
In the elderly, there is a natural decline of gluco-regulation.
Messier et al.(110) compared the cognitive performance of
older participants, aged 55–84 years, with better glucose
regulation with those with poorer glucose regulation (as
measured by the increase in blood glucose from a fasting to
peak level following a glucose tolerance test). It was observed
that older participants with poorer glucose regulation were
impaired in several tests, including verbal memory and arith-
metic tasks(110). Some studies have also detected cognitive
effects associated with impaired glucose regulation in younger
participants, although the impairment is less noticeable in
comparison with older participants(111,112). It has been found
that those with poorer glucose regulation performed worse
on several verbal declarative measures, including immediate
and delayed paragraph recall, verbal-free recall and order
reconstruction tasks(111). Donohoe & Benton(113) performed
a glucose tolerance test on undergraduate students and
measured blood glucose levels every 30 min following inges-
tion of a glucose drink. They observed that between 2 and
3 h after the ingestion of 50 g glucose, there was a dip in
blood glucose below fasting levels that was followed shortly
by a return to fasting levels. They found that the quicker
the return to fasting levels, the better the performance on
cognitive tests of memory consolidation and retrieval. Other
measures of glucose levels did not correlate with memory
performance except that faster reaction time was found to
be associated with higher baseline blood glucose during the
test performance.
A number of other gluco-regulatory indices have been
previously evaluated for their relationship with cognitive
performance in both younger and older participants. These
include fasting blood glucose levels, peak glucose levels,
recovery and evoked glucose to baseline levels and incremen-
tal area under the curve. Overall evidence suggests that gluco-
regulation may exert direct effects on cognitive function so
that those with poor gluco-regulation demonstrate mild
cognitive deficits in comparison with those with good gluco-
regulation(99,101,111,113–119). However, there is evidence to
suggest that a long-term deficit in gluco-regulation may
also result in chronic cognitive impairments(120) and be a con-
tributing factor in the development of ARCD and dementia(28).
A number of epidemiological studies have provided evidence
to suggest that type 2 diabetes is a significant risk factor
for developing dementia(83,121–123).
Whey protein, obesity and glucose regulation
In bovine milk, whey protein consists of a-lactalbumin, b-lacto-
globulin, IgG, serum albumin, IgA and trace amounts of
lactoferrin(124). In terms of protein in the diet, it has been
previously observed that free consumption of a high-protein
diet increases the rate of fat loss in obese subjects compared
with those on low-protein diets(125). It is believed that
weight loss by increased density of protein in the diet is due
to increased satiety leading to reduced total energy intake
coupled with greater total energy expenditure (due to
increased thermogenesis from protein digestion)(126). However,
these studies have used mixed protein meals, with more
recent research suggesting that the type of protein may be
of particular importance for improving body composition.
Current evidence suggests that ‘complete’ proteins that contain
all essential amino acids show larger increases in energy
expenditure following consumption in comparison with
lower-quality proteins(127). Whey protein is not only more
complete than other forms of protein such as egg albumin
or protein derived from red meat, but also it may offer
additional benefits. It is high in branched-chain amino acids,
in particular leucine, which means whey is particularly
beneficial for preventing muscle-wasting during weight-loss
programmes(128). In terms of fat reduction, whey protein con-
centrate has been shown to reduce body weight in rats(129,130),
whereas increased dietary red meat has been demonstrated
to increase body weight in rats(129). In a clinical trial with
elderly women, a 15 d whey supplement was also found to
significantly lower body weight(131).
Obesity has been found to be a significant factor in the
development of insulin resistance, due to chronic systemic
inflammation in adipose tissue(132). Furthermore, in elderly
subjects, there is also a natural decline of gluco-regulation(110).
Therefore, any dietary intervention which assists in the main-
tenance of healthy body weight may also assist in maintaining
efficient glucose regulation, which, as mentioned previously,
results in better cognitive function both acutely and
chronically(100,101,120). In a recent study by Belobrajdic et al.(133),
insulin-resistant rats fed a high-whey-protein diet for 6 weeks
have been found to have significantly reduced energy intake
and body fat. In comparison with rats receiving protein in
the form of red meat, rats receiving the high-whey-protein
diet have also been found to have significantly lower weight
gain and significantly increased insulin sensitivity. The authors
concluded that the improved insulin sensitivity was due to a
reduction of visceral fat.
Abnormal insulin levels and dementia
Early-stage AD has been found to be associated with high
insulin concentrations in response to glucose challenge
(hyperinsulinaemia) in combination with reduced insulin-
mediated glucose uptake (insulin resistance) in a number of
individuals(134). In the central nervous system (CNS), insulin
has the effect of promoting the release of intracellular
Ab(135), with aggregation of Ab known to be a central feature
of AD pathophysiology(31). In chronic peripheral hyperinsuli-
naemia, insulin crosses the blood–brain barrier and promotes
an increase in the release of Ab into extracellular compart-
ments(28). Due to high plasma levels of insulin, there will
also be increased concentrations of peripheral Ab that will
result in obstruction to the clearance of Ab from the
brain(28). Furthermore, increased levels of insulin in the CNS
also inhibit the degradation of Ab. This is because insulin-
degrading enzyme plays an important role in clearing intra-
cellular Ab(136,137), and when there are high levels of insulin
in the brain, it must compete with insulin as a target(28).
D. A. Camfield et al.162
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However, with sustained high levels of insulin in the brain,
there is an eventual down-regulation of insulin transport into
the brain and inhibition of brain synthesis of insulin(138,139).
With a lowered level of insulin in the brain, there is a
reduction in the release of Ab from intracellular compartments
as well as a reduction in insulin-degrading enzyme, also
bringing about reduced clearance of Ab from the brain(28).
Furthermore, a reduction in ACh and cerebral blood flow
has also been found to be associated with low concentrations
of insulin in the CNS(140). Thus, both increased and decreased
insulin concentrations in the brain contribute to the pathogen-
esis of AD. In addition to Ab aggregation, there is also evi-
dence to suggest that low brain concentrations of insulin
may lead to an increase in tau hyperphosphorylation(141),
while high peripheral insulin levels have been found to exacer-
bate central inflammation(142,143) and oxidative stress(144).
Influence of whey protein on insulin release
Milk products, in particular the whey fraction, have been
found to have an insulinotropic effect both in normal subjects
and type 2 diabetics(74,145,146). Whey is a rapidly digested
protein, which promotes a higher concentration of amino
acids in the plasma following its consumption(147). Amino
acids are known to stimulate insulin release in the pancreatic
b-cell(148). Nilsson et al.(149) reported that the branched-chain
amino acids leucine, isoleucine and valine, together with
lysine and threonine, were the most efficient insulin secretago-
gues. Table 2 displays the typical amino acids found in whey,
together with the quantities (mg/g) from the study by Nilsson
et al.(149).
The benefit of acute increases in insulin secretion following
the consumption of whey protein is that the resultant peak in
blood glucose is not as high as it otherwise would be. Frid
et al.(146) reported that the plasma glucose 180 min area
under the curve was reduced by 21 %, when whey was
included in the lunch meal in comparison with a reference
meal containing ham. Reducing the postprandial glucose
peak has been suggested as a more effective means of
treating diabetes than targeting fasting blood glucose
levels(150). Epidemiological evidence suggests that, even among
overweight individuals, regular dairy product consumption is
associated with a significantly lower incidence of the insulin
resistance syndrome(69). In light of the evidence suggesting
that consumption of dairy products may have a positive
effect on glucose regulation(46), it is feasible that there may
be acute, as well as chronic, cognitive benefits associated
with regular consumption.
Dairy constituents as direct modulators of cognition
In addition to the cognitive benefits of dairy products associ-
ated with improvement to gluco-regulation, there are also a
number of components of dairy products that have the poten-
tial to influence brain function directly. The composition of
milk will be used as an example of the typical components
found in dairy products(151): water (85·5–88·7 %), milk fat
(2·4–5·5 %) and solids (non-fat, 7·7–10 %). The composition
of the milk solids may be summarised as follows: lactose
4·6 %, protein 3·25 % (80 % caseins, 20 % whey proteins, e.g.
a-lactalbumin and b-lactoglobulin), minerals 0·65 % (Ca, P,
Mg, K, Na, Zn, Cl, Fe, Cu and sulphate), acids 0·18 % (citrate,
formate, acetate, lactate and oxalate), enzymes (peroxidase,
catalase, phosphatase and lipase) and vitamins (A, B12, C, D,
thiamin and riboflavin). A growing body of research has
now reported positive effects on brain function and cognitive
ability that are associated with a number of the components of
dairy products.
Bioactive peptides
Biologically active peptides have been defined as protein frag-
ments that have a positive impact on bodily functions or con-
ditions and may ultimately influence health(152). Milk proteins
act as precursors for the formation of bioactive peptides, with
the size of the active sequences varying from two to twenty
amino acids(152). Casein represents a major proportion (80 %)
of the protein content in bovine milk, and contains a large
quantity of branched-chain amino acids(153). Phosphorylated
regions are contained in bovine as1-casein, as2-casein and
b-casein, regions that may subsequently be released by
digestive enzymes(154). The digestive enzymes such as
pepsin, trypsin and chymotrypsin have been shown to release
a variety of different peptides through hydrolysis of both
the casein and whey proteins found in milk. Bioactive pep-
tides are also produced through fermentation of milk with
starter cultures, or proteolysis by plant or micro-organism
enzymes(155). However, yogurt, cheese and probiotic bacteria
have been found to produce different bioactive peptides
during milk fermentation(156). Additionally, a great variety of
bioactive peptides have also been found to be formed
during the cheese-ripening process; e.g. Parmigiano-
Reggiano, b-casein f(8–16), f(58–87), as2-casein f(83–88);
Gouda, as1-casein f(1–9), b-casein f(60–68); Festivo,
as1-casein f(1–9), f(1–7), f(1–6); Italian varieties of Mozzarella,
Crescenza, Italico and Gorgonzola, b-casein f(58–72)(154).
Table 2. Amino acids in whey*
Amino acid mg/g
Glu 141·4
Asp 94·1
Leu† 79·8
Lys 76·1
Thr 61·1
Val† 59·3
Ile† 57·3
Pro 46·7
Ala 42·1
Ser 38·8
Cys 22·8
Arg 22·0
Phe 21·3
Tyr 20·8
Met 19·4
His 18·7
Gly 13·8
* Adapted from Nilsson et al.(149).
† Branched-chain amino acids.
Dairy constituents and neurocognitive health 163
B
ri
ti
sh
Jo
u
rn
al
o
f
N
u
tr
it
io
n
A range of different functions have been studied in relation
to the biologically active peptides. The most intensively stu-
died function has been that of the blood pressure-reducing
(hypotensive) peptides, which inhibit angiotensin-converting
enzyme I(157,158). There is evidence to suggest that the angio-
tensin-converting enzyme I inhibitory potency of cheese
increases during the ripening process(159). Casein-derived bio-
active peptides with varying angiotensin-converting enzyme I
inhibitory potencies have been isolated from a variety of Ita-
lian cheeses: Crescenza (37 % inhibition), Mozzarella (59 %
inhibition), Gorgonzola (80 % inhibition) and Italico (82 %
inhibition)(160). In feeding experiments using spontaneously
hypertensive rats, reductions in systolic blood pressure have
been found to be significant 6 h following ingestion of the
cheese varieties Gouda, Blue, Edam and Harvati(161).
A number of bioactive peptides have also been found to be
opioid receptor ligands with agonistic or antagonistic activities.
b-Casomorphins, which are hydrolysed fragments of b-casein,
were the first opioid peptides to be discovered. The adult
human intestine has not been found to be permeable to caso-
morphins, as there has been a failure to detect their presence
in the blood plasma following ingestion(162). For this reason,
the opioid effects of casomorphins are believed to occur
only at a peripheral level, causing a reduction in intestinal
transit time and modulating the absorption of amino acids
and the transport of electrolytes(163). However, casomorphins
have been detected in the plasma of neonates due to their
greater intestinal permeability, and, for this reason, it has
been suggested that infant formulas may exert a sedative
effect on the newborn child(164). Exorphins are another class
of milk protein-derived opioids, which include a-lactorphin
peptides corresponding to bovine as1-casein f(90–96) and
bovine a-lactalbumin f(50–53); and b-lactorphin peptides
corresponding to bovine b-lactoglobulin f(102–105)(165). The
exorphins have been shown to exert weak opioid activity in
smooth muscles, having a positive effect on the cardiovascular
system through vasorelaxation. However, these peptides do
not easily cross the blood–brain barrier and have not been
found to exert effects in the CNS(166).
Peptides with a range of other functions have also been
identified, including Ca-binding phosphopeptides as well as
antibacterial and immunomodulatory peptides(155). With
particular relevance to nervous system function and the
enhancement of cognitive ability, a number of bioactive
peptides have also been found to have antioxidative proper-
ties. In a review of antioxidative peptides derived from milk,
Pihlanto(167) identified six peptide fragments derived
from casein as well as three peptide fragments derived from
b-lactoglobulin, which exerted radical-scavenging abilities
and inhibited lipid peroxidation: as1-casein f(144–149), b-casein
f(98–105), b-casein f(177–183), b-casein f(169–176),
b-casein f(170–176), k-casein f(96–106), b-lactoglobulin
f(19–29), b-lactoglobulin f(145–149), b-lactoglobulin f(42–46).
It was noted that antioxidative peptides that had been ident-
ified so far all contained one or more residues of histidine,
proline, tyrosine and tryptophan. Preclinical and clinical
studies with fermented milk products have provided prelimi-
nary evidence of antioxidant effects associated with these
products. Whey proteins in conjunction with lactic acid bac-
teria have been shown to have an antiperoxidative action in
rats deficient in vitamin E(168). Similarly, in a human clinical
intervention study, 21 d supplementation with 150 g/d fermen-
ted goats’ milk was found to prolong the resistance of the lipo-
protein fraction to oxidation, lower the levels of peroxidised
lipoproteins, oxidised LDL, 8-isoprostanes and glutathione
redox ratio, and enhance total antioxidative activity(169).
A recent study by Zemel et al.(170) has also revealed a significant
reduction in both oxidative and inflammatory stress in over-
weight and obese participants following a 21 d dairy-rich diet.
An important issue to consider is the concentrations of
bioactive peptides that are required in order to have a clini-
cally significant effect. The natural concentrations of bioactive
proteins found in dairy products are quite low(124,166). Consid-
ering that many of the purported physiological effects of
bioactive peptides are currently based on in vitro research(166),
there is a need to conduct clinical trials in humans in order to
determine the dose required for clinical effects. A number of
techniques are currently under development in order to isolate
and enrich the different proteins found in milk. Microbial
fermentation using lactic acid bacteria applied to protein-rich
raw material is a technique that has the potential to enable
large-scale production of bioactive peptides for human
consumption(124).
A number of commercially available bioactive peptides
have recently become available(154), which may form the
basis for future clinical intervention studies in humans. To
date, only a handful of clinical studies, largely in relation to
antihypertensive bioactive peptides, have been conducted in
humans, using milk protein hydrolysates or fermented milk
products(171–175). However, a clinical study by Nakamura
et al.(153) has been one of the few studies to examine cognitive
effects following intake of a milk casein hydrolysate (0·2 g/kg).
The authors reported increased oxyhaemoglobin concen-
tration in the prefrontal cortex and improvements to work effi-
ciency following an acute stressor 60 min after ingestion.
These findings corroborated the results of a previous study
investigating the effects of a soya protein hydrolysate on
brain function(176), although the mechanism of action is
unclear. Further clinical trials investigating the efficacy of bio-
active peptides in enhancing cognitive function, both acutely
and chronically, are currently needed.
Colostrinin and proline-rich polypeptides
Proline is an amino acid that occurs widely in the proteins of
both prokaryotic and eukaryotic cells, with a high number of
proline residues found in milk caseins(151). Proline has an unu-
sual chemical structure, characterised by a side-chain that is
cyclised back on to the backbone amide position. For this
reason, proline-rich polypeptides create disturbance in protein
structure and are highly bioactive molecules(177). Particularly,
high concentrations of proline residues are found in the colos-
trum, which is the pre-milk fluid produced by the mammary
glands of mammals in late pregnancy. The constituents of
the colostrum are designed to boost the immunity of the new-
born mammal as well as to promote the maturation of the
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CNS(178). A comparison of the major milk proteins found in
normal milk and the colostrum is displayed in Table 3.
Here, it can be seen that there are higher quantities of
a-lactalbumin, b-lactoglobulin and immunoglobulins in the
colostrum compared with normal milk. The difference is
particularly large for immunoglobulins.
Colostrum-derived proline-rich polypeptides are known as
Colostrinine (CLN), and are obtained from bovine colostrum
according to a patented method using alcohol extraction and
filtration(179). CLN can be taken in the form of a tablet or cap-
sule and has been characterised as a new cytokine that stimu-
lates a general immune response(180). The yield of proline-rich
polypeptides is found to be highest within 6 h of delivery(181).
CLN consists of approximately 22 % proline, as well as a
high proportion of non-polar amino acids, low percentages
of glycine, alanine, arginine and histidine and no residues of
tryptophan or cysteine(182).
CLN has been found to be effective in reducing oxidative
stress, with the research by Zablocka et al.(183) providing
evidence that CLN regulates cytokine secretion and inhibits
the production of the superoxide anion and NO in vivo.
There is also evidence to suggest that CLN has a protective
effect against mitochondrial dysfunction and Ab-induced
apoptosis of neurons(178). Furthermore, CLN has been found
to improve both spatial learning and incidental memory
in rats(184). Some preliminary clinical studies have been
conducted to investigate the potential of CLN as a treatment
of ARCD and AD.
In a double-blind study of CLN in AD, Leszek et al.(185)
administered CLN, Se or placebo to forty-six AD patients
over a 12-month period. A statistically significant improvement
in mini-mental state examination score at 12 months was
found in those patients receiving CLN who entered the
study with mild AD. A trend towards improved outcome
was also found for patients receiving CLN who entered the
study with moderate or severe AD. CLN was found to be sig-
nificantly more effective than both placebo and Se in treating
AD, with 50 % of the CLN-treated patients showing improve-
ment, while only 5 % of Se-treated patients showing improve-
ment, and none in the placebo group. In a randomised
controlled study by Bilikiewicz & Gaus(186), CLN or placebo
was administered to 105 Polish patients with mild-to-moderate
AD over a 15-week period. ADAS-cog scores were found to be
significantly higher in patients receiving CLN compared with
placebo after 15 weeks. The overall benefit analysis revealed
that 40 % of patients either stabilised or improved on CLN as
opposed to only 21 % on placebo.
a-Lactalbumin
a-Lactalbumin comprises approximately 3·4 % of the total pro-
tein content of bovine milk(187) and is the predominant whey
protein in human milk, with levels increasing from 21 to 34 %
between days 1 and 14 of lactation(188). In addition to the bio-
active peptides that result from the partly hydrolysed protein,
there are also a number of important amino acids that are
released from the fully digested protein. a-Lactalbumin is a
particularly good source of the essential amino acids trypro-
phan and cysteine. Tryptophan is a precursor of serotonin
(5-hydroxytryptamine, 5-HT), while cysteine is a precursor
of the endogenous antioxidant glutathione(189). a-Lactalbumin
protein contains the highest tryptophan content of all food
protein sources (6 %)(190). By increasing the blood plasma
ratio of tryptophan:other large amino acids, there is greater
transport of tryptophan across the blood–brain barrier,
which results in enhanced 5-HT synthesis in the brain(191).
Previously, it has been demonstrated that a-lactalbumin
containing 1·3 g tryptophan/100 g causes a 48 % increase in
plasma tryptophan:large neutral amino acids(192), and more
recently, it has been observed that evening consumption of
a-lactalbumin with a tryptophan content of 4·8 g/100 g
increased plasma tryptophan by 130 %(193). Furthermore, in
preclinical research with rodents, a-lactalbumin has been
found to increase brain 5-HT concentrations(194). Raising
brain serotonin might have a number of beneficial effects on
mood and cognitive function. In terms of stress, raised seroto-
nin might attenuate the effects of reduced neurogenesis that
occurs following stress and throughout the ageing pro-
cess(195). In terms of sleep, serotonin up-regulation may
improve sleep deficiencies and abnormalities affecting cogni-
tion, which occur in young and elderly individuals due to
deficient brain 5-HT activity(196).
Behavioural findings show that serotonin raised by a-lactal-
bumin restores sleep in rats that are sleep-deprived through
food deprivation(197). In humans, increases in plasma trypto-
phan availability for uptake into the brain have been shown
to enhance sustained alertness early in the morning after an
overnight sleep, a finding that has been attributed to improved
sleep(193). Furthermore, a-lactalbumin has been shown to
improve mood and information processing, as well as to
attenuate stress-induced cortisol responses in stress-vulnerable
subjects (with high neuroticism scores) but not in controls
(low neuroticism scores)(198,199). Research by Schmitt
et al.(200) in premenstrual women, who typically display sero-
tonergic hypofunction, revealed that acute administration of
a-lactalbumin protein ameliorated memory performance defi-
cits in long-term memory for abstract figures.
Since the serotonin system is important in the regulation of
mood as well as cognitive function, the use of a-lactalbumin
to relieve depressive symptoms has also previously been
investigated. The current treatments for depression largely
work by inhibiting the reuptake of serotonin (preventing
breakdown and reabsorption in order to increase circulating
serotonin). Selective serotonin re-uptake inhibitors have
been found to relieve depressive symptoms in both animal
and human models(201). Conversely, depletion of tryptophan
Table 3. Concentration of the major proteins of bovine
colostrum and milk*
Concentration (g/l)
Protein Colostrum Milk
Caseins (as1, as2, b and k) 26 28
b-Lactoglobulin 8·0 3·3
a-Lactalbumin 3·0 1·2
Immunoglobulins 20–150 0·5–1·0
* Adapted from Korhonen & Pihlanto(124).
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induces depressive symptoms in depression-vulnerable indi-
viduals (for a review, see Booij et al.(202)). In preclinical
research with rats, a-lactalbumin-enriched diets have been
found to enhance serotonin release and induce anxiolytic
(antipanic or anti-anxiety agent) and rewarding effects(194).
However, in humans, recovered depressive individuals and
control subjects who were subjected to a laboratory stressor
showed only modest improvements to mood and cortisol
response to experimental stress following acute administration
of a drink containing 20 g a-lactalbumin(203). The authors
suggested that acute administration of a-lactalbumin was not
sufficient to prevent a stress-induced mood deterioration or
cortisol response(203) in recovered depressed subjects. In a
later study, also examining the effects of a-lactalbumin in
recovered depressed patients, again, significant improvement
to mood has been observed. However, both recovered
depressive subjects and control subjects demonstrated
improved cognitive ability following a-lactalbumin adminis-
tration(204). In a recent study by Verschoor et al.(205), acute
administration of a drink containing 20 g a-lactalbumin has
not been found to significantly affect the mood or appetite fol-
lowing an acute stressor, although a lower liking for sweet
foods has been observed in those with high trait anxiety.
Taken together, the data suggest that enhancing 5-HT function
through dietary tryptophan may be beneficial for improving
sleep, mood and cognitive functioning and may particularly
benefit vulnerable individuals coping with high levels of
stress. However, it is important to note that the clinical studies
reviewed have used drinks with the levels of a-lactalbumin far
in excess of that which would be found in normal dairy pro-
ducts. As shown in Table 3, 1·2 g a-lactalbumin per litre is typi-
cally found in normal milk, which is a much smaller quantity
in comparison with the 20 g typically used in intervention
studies(203–205). Thus, in order to see clinically significant
effects on cognition or mood associated with a-lactalbumin,
a drink with fortified levels would need to be taken.
Vitamin B12
Dairy products are a natural dietary source of vitamin B12, with
one cup of yogurt providing about 25 % of the recommended
daily intake, and one cup of milk contributing about 10 % of
the recommended daily intake of B12
(206). Maintaining ade-
quate dietary levels of B12 is important for healthy brain
ageing, with epidemiological research linking vitamin B12
deficiency to a greater risk of developing AD(22,207,208).
A study by Wang et al.(209) has reported that out of 370 elderly
people monitored over a 3-year period, vitamin B12 as well as
folate deficiency was associated with double the risk of
developing AD. Research by Nilsson et al.(210) has reported
decreased serum vitamin B12 levels in 69 % of demented and
non-demented psychogeriatric patients. In another study,
this group reported significant improvement to mini-mental
state examination scores in a mild-to-moderate dementia
group following 2-month treatment with vitamin B12 as well
as folate(211). Unfortunately, the majority of epidemiological
studies do not consider vitamin B12 in isolation from folate,
and for this reason, it is difficult to discern the relative
contribution of each to the risk of developing dementia.
However, current theoretical understanding regarding the
relationship between B12 deficiency and accumulation of the
amino acid HCy suggests that it plays an important role in
the maintenance of healthy brain function(212).
There is strong evidence to suggest that vitamin B12
deficiency brings about cognitive decline due to an excess
build-up of the amino acid HCy. Vitamin B12, together with
folate, is a cofactor for enzymes that recycle HCy back to meth-
ionine, and when they are not present in adequate amounts,
the methionine–HCy cycle is disrupted, which has a significant
impact on cognitive function(212). HCy, an amino acid pro-
duced by the metabolism of methionine, has been found to
be a biomarker in its own right for elevated risk of developing
AD. HCy is normally metabolised in one of two ways; it is either
converted back to methionine by re-methylation or converted
to taurine and cysteine through trans-sulfuration. Abnormally
high levels of HCy signal a breakdown in these biochemical
processes. If not enough HCy is converted back to methionine,
this has important implications for brain function(212).
The methionine cycle involves the conversion of methion-
ine to S-adenosylmethionine, which is the most important
methyl donor in the human body required for methylation
of a host of substances, including DNA and proteins such as
myelin. After donating its methyl group, S-adenosylmethio-
nine becomes S-adenosylhomocysteine and then HCy after
losing its adenosine. If HCy is not metabolised properly,
there will be insufficient S-adenosylmethionine available,
and this will result in the inhibition of methylation(212). The
gene for the amyloid precursor protein is heavily methylated.
Decreased methylation may lead to the promotion of gene
mutations involved in the increased expression of amyloid
precursor protein and extracellular deposition of the Ab pep-
tide(213,214). Furthermore, accumulation of HCy itself, as well
as S-adenosylhomocysteine, in the body has been found to
cause oxidative stress, excitotoxicity in neurons, as well as
DNA strand breakage and mitochondrial membrane
damage(215). There is also evidence to suggest that excess
HCy makes neurons more sensitive to Ab toxicity(216).
Total levels of plasma HCy have been found to increase
with age, reaching a plateau at about the age of 60
years(217). In a study of HCy levels in histologically confirmed
AD patients by Clarke et al.(218), it has been found that people
in the top third of HCy levels had a 4·5 times greater risk of AD
compared with those in the bottom third. The Framingham
Study(217), which followed up 1092 people for 8 years, has
found high HCy levels to be associated with double the risk
for AD. A more recent 4·5-year longitudinal study by Haan
et al.(22) on 1779 Mexican Americans over the age of 60
years reported 2·39 times the risk of dementia or cognitive
impairment associated with high HCy levels at baseline.
High levels of HCy are concomitantly observed with low
levels of the recycling cofactors vitamin B12 and folate. In a
study by Joosten et al.(219) comparing fifty-two AD patients
with forty-nine elderly people living at home and fifty hospi-
talised non-demented controls, the AD group has been
found to have the highest levels of HCy and the lowest
levels of vitamin B12. The evidence thus far implicates vitamin
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B12 as an important vitamin for maintaining proper metab-
olism of HCy, without which the brain becomes more suscep-
tible to oxidative damage and apoptosis. As an important
dietary source of vitamin B12, dairy products are likely to
play an important role in ensuring adequate HCy metabolism,
particularly during ageing.
Calcium
It has been estimated that dairy products contribute 70·3 % of
Ca in the US diet(220). If dairy products are excluded from the
diet, then it is difficult to meet the recommended Ca
intake(221). There is strong evidence from both epidemiologi-
cal studies and randomised clinical trials to suggest that
higher consumption of dairy products may be associated
with lower rates of obesity(222). One mechanism by which
dairy products may lead to weight reduction is an increase
in satiety due to the consumption of dairy proteins(223).
However, perhaps the most significant contribution to
weight loss associated with dairy product consumption is
due to the impact of Ca on fat excretion. A meta-analysis by
Astrup et al.(222) has revealed that increasing dairy Ca
consumption by 1200 mg/d resulted in increased faecal fat
excretion by 5·2 g/d. Ca forms insoluble fatty acid soaps and
other hydrophobic aggregations of bile acids, P and fatty
acids in the small intestine, resulting in a greater excretion
of fat(224,225). Serum cholesterol levels have also been found
to be lowered following supplementation with calcium phos-
phate, as a result of increased bile excretion and regeneration
of bile acids from endogenous cholesterol(226).
In contrast to the positive effects of Ca on obesity and
cholesterol, there have been some concerns regarding high
intakes of Ca and increased vascular calcification. A cross-
sectional study by Payne et al.(227) has found evidence to
suggest that Ca and vitamin D intake was positively correlated
with brain lesion volume in a sample of elderly adults.
Similar findings were reported by Bolland et al.(228) in a Ca
supplementation study of bone mineral density in elderly
women. Those women randomised to receive Ca supplemen-
tation were found to be twice as likely of suffering a myocar-
dial infarction in comparison with the placebo group over a
5-year period. A recent supplementation study by Daly
et al.(229) has also reported that abdominal aortic calcification
increased in men receiving Ca and vitamin D3 fortified milk in
comparison with the control group over a 2-year period.
Further research is currently needed in order to determine
the dose at which vitamin D and/or Ca increases the risk of
vascular calcification.
Ca dysregulation has been proposed as an important factor
in brain ageing and neurodegeneration(27,230) as well as in the
metabolic syndrome(231). Larger Ca2þ-dependent afterhyper-
polarisation associated with action potentials has been found
in cortical and hippocampal neurons of older compared
with younger animals(232–237). Larger Ca2þ transients during
repetitive spike trains(238,239), larger whole-cell Ca2þ cur-
rents(240) and excess Ca2þ influx into neurons via voltage-
gated Ca2þ channels have also been found to be associated
with ageing, with many of these changes also found to be
associated with age-related cognitive deficits(230,241). Elevated
Ca2þ release from ryanodine receptors is a contributing
factor to cell death(230), with ryanodine receptor expression
altered in some AD mutations (e.g. presenilin 1)(232,242).
However, it is important to note that there is currently no
evidence to suggest that dietary intake of Ca is a causative
factor in age-related Ca dysregulation.
Probiotics
Probiotics are live microbial food supplements that have a
beneficial effect on intestinal microbial balance, with the
most frequently used bacteria in commercially available
fermented milk and yogurts being the Lactobacillus and
Bifidobacterium species(243). The research assessing the effects
of probiotics on brain function is in its very early stages.
However, research suggests that bacteria in the gastrointestinal
tract can communicate with the CNS, and may have immune-
and non-immune-related effects beyond the gastrointestinal
tract(243). Studies on clinical populations such as the chronic
fatigue syndrome and fybromyalgia, where lower levels of
bifidobacterium and higher levels of lactic acid bacteria
have been reported, have found evidence to suggest that
poorer gut health is correlated with more severe neurological
and cognitive deficits such as nervousness, memory loss,
forgetfulness and confusion(244).
A possible explanation for the link between gut health and
cognition is the effect of pro-inflammatory cytokines in the
CNS. It has been suggested that the effect of probiotics on
systemic inflammatory cytokines and oxidative stress may
ultimately lead to an increase in brain-derived neurotrophic
factor(245). A preclinical study by Desbonnet et al.(246)
has revealed that 14 d of treatment with the probiotic
Bifidobacterium infantis resulted in a significant attenuation
of pro-inflammatory cytokines, together with a significant
increase in the serotonin precursor tryptophan. These findings
are indicative of an antidepressant effect, and have led to the
recent suggestion that probiotics may be used as an adjunct
treatment for major depressive disorder(245).
There have been few studies to directly assess the effects of
probiotics on cognition. A study by Benton et al.(247) has been
one of the few chronic intervention studies to directly investi-
gate the effects of probiotics on cognition. However, the
effects on cognition were not in the direction that might
have been expected. At day 20 of the intervention, individuals
in the probiotic group were found to perform significantly
worse on a test of semantic memory in comparison with
placebo. However, considering the scarcity of other studies
to investigate the cognitive effects associated with probiotics,
further research is required to corroborate these findings.
Summary
The use of dairy products in the prevention or amelioration of
normal ARCD and dementia is of growing interest. A number
of components present in dairy products may have a substan-
tial impact on the physiological factors associated with ageing
and dementia. As with other dietary interventions which
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influence cognitive function, the impact of dairy products on
neurocognition is modulated by individual differences. Some
of these may be specific to dairy, such as lactose intoler-
ance(248), although the area is rather under-researched. Dairy
consumption, in particular low-fat dairy, has been found to
be associated with a lowered incidence of the metabolic syn-
drome, with positive effects on cognition through improved
glucose regulation and weight management associated with
whey protein and Ca. In order to reduce the health risks
associated with saturated fats, it is recommended that low-fat
dairy be consumed as part of the regular diet in preference
to high-fat dairy. A number of bioactive peptides originating
from dairy products have been found to have a beneficial
effect on cardiovascular function, as well as on antioxidant
and anti-inflammatory properties. However, the natural
concentrations of these peptides are relatively low, and man-
ufacturing techniques are currently needed in order to further
isolate and enrich these beneficial peptides. CLN is a form of
dairy product that has been found to be effective in reducing
oxidative stress and inflammation, and has shown potential in
the treatment of patients with mild AD. a-Lactalbumin from
whey protein has been found to be beneficial in increasing
the levels of serotonin, with preliminary data suggesting
potentially beneficial effects on sleep, mood and cognition,
particularly in individuals vulnerable to stress. However,
currently, the quantity of a-lactalbumin found in normal
milk is inadequate to achieve clinically significant effects,
and for this reason, the quantity must be fortified. Vitamin
B12 has been found to be an important dietary constituent
that is required for effective HCy metabolism, with dairy pro-
ducts being a major source of vitamin B12 in the diet. Dairy
products are also a major source of dietary Ca, with Ca con-
sumption associated with lower rates of obesity and lowered
serum cholesterol levels. However, there has been some con-
cern that increased Ca intake may be linked to an increase in
vascular calcification. Probiotics have also been found to have
a positive effect on neurocognitive health by attenuating pro-
inflammatory cytokine activity and increasing levels of trypto-
phan and brain-derived neurotrophic factor. In conclusion,
current evidence suggests that the regular consumption of
low-fat dairy products as part of a balanced diet may have a
number of positive effects on neurocognitive health in ageing.
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potentiates Î2-amyloid neurotoxicity: role of oxidative
stress. J Neurochem 78, 249–253.
217. Elias MF, Sullivan LM, D’Agostino RB, et al. (2005) Homo-
cysteine and cognitive performance in the Framingham
Offspring Study: age is important. Am J Epidemiol 162,
644–653.
218. Clarke R, Smith AD, Jobst KA, et al. (1998) Folate, vitamin
B12, and serum total homocysteine levels in confirmed
Alzheimer disease. Arch Neurol 55, 1449–1455.
219. Joosten E, Lesaffre E, Riezler R, et al. (1997) Is metabolic
evidence for vitamin B-12 and folate deficiency more
frequent in elderly patients with Alzheimer’s disease?
J Gerontol A Biol Sci Med Sci 52, M76–M79.
220. US Department of Health and Human Services & US
Department of Agriculture (2005) Dietary Guidelines for
Americans, 6th ed. Washington, DC: US Government.
http://www.health.gov/dietaryguidelines.
221. Gao X, Wilde PE, Lichtenstein AH, et al. (2006) Meeting
adequate intake for dietary calcium without dairy foods
in adolescents aged 9 to 18 years (National Health and
Nutrition Examination Survey 2001–2002). J Am Diet
Assoc 106, 1759–1765.
222. Astrup A, Chaput JP, Gilbert JA, et al. (2010) Dairy
beverages and energy balance. Physiol Behav 100, 67–75.
223. Major GC, Chaput JP, Ledoux M, et al. (2008) Recent
developments in calcium-related obesity research. Obes
Rev 9, 428–445.
224. Govers MJAP, Termont DSML, Van Aken GA, et al. (1994)
Characterization of the adsorption of conjugated and
unconjugated bile acids to insoluble, amorphous calcium
phosphate. J Lipid Res 35, 741–748.
225. Gacs G & Barltrop D (1977) Significance of Ca soap
formation for calcium absorption in the rat. Gut 18, 64–68.
226. Ditscheid B, Keller S & Jahreis G (2005) Cholesterol metab-
olism is affected by calcium phosphate supplementation in
humans. J Nutr 135, 1678–1682.
227. Payne ME, Anderson JJB & Steffens DC (2008) Calcium and
vitamin D intakes may be positively associated with brain
lesions in depressed and nondepressed elders. Nutr Res
28, 285–292.
228. Bolland MJ, Barber PA, Doughty RN, et al. (2008) Vascular
events in healthy older women receiving calcium
supplementation: randomised controlled trial. BMJ 336,
262–266.
229. Daly R, Ebeling P, Khan B, et al. (2009) Effect of calcium–
vitamin D3 fortified milk on abdominal aortic calcification
in older men: retrospective analysis of a 2-year randomized
controlled trial. J Bone Miner Res 24, 1215.
230. Thibault O, Gant JC & Landfield W (2007) Expansion of the
calcium hypothesis of brain aging and Alzheimer’s disease:
minding the store. Aging Cell 6, 307–317.
231. Levy J, Gavin JR 3rd & Sowers JR (1994) Diabetes mellitus: a
disease of abnormal cellular calcium metabolism? Am J Med
96, 260–273.
232. Stutzmann GE, Smith I, Caccamo A, et al. (2006) Enhanced
ryanodine receptor recruitment contributes to Ca2þ disrup-
tions in young, adult, and aged Alzheimer’s disease mice.
J Neurosci 26, 5180–5189.
233. Potier B, Rascol O, Jazat F, et al. (1992) Alterations in the
properties of hippocampal pyramidal neurons in the aged
rat. Neuroscience 48, 793–806.
234. Landfield PW & Pitler TA (1984) Prolonged Ca2þ-dependent
afterhyperpolarizations in hippocampal neurons of aged
rats. Science 226, 1089–1092.
235. Kerr DS, Campbell LW, Hao SY, et al. (1989) Corticosteroid
modulation of hippocampal potentials: increased effect
with aging. Science 245, 1505–1509.
236. Moyer JR Jr, Thompson LT, Black JP, et al. (1992) Nimodi-
pine increases excitability of rabbit CA1 pyramidal neurons
in an age- and concentration-dependent manner. J Neuro-
physiol 68, 2100–2109.
237. Disterhoft JF, Thompson LT, Moyer JR Jr, et al. (1996)
Calcium-dependent afterhyperpolarization and learning
in young and aging hippocampus. Life Sci 59, 413–420.
238. Hemond P & Jaffe DB (2005) Caloric restriction prevents
aging-associated changes in spike-mediated Ca2þ accumu-
lation and the slow afterhyperpolarization in hippocampal
CA1 pyramidal neurons. Neuroscience 135, 413–420.
239. Thibault O, Hadley R & Landfield PW (2001) Elevated post-
synaptic [Ca2þ]i and L-type calcium channel activity in aged
hippocampal neurons: relationship to impaired synaptic
plasticity. J Neurosci 21, 9744–9756.
240. Campbell LW, Hao SY, Thibault O, et al. (1996) Aging
changes in voltage-gated calcium currents in hippocampal
CA1 neurons. J Neurosci 16, 6286–6295.
241. Thibault O & Landfield PW (1996) Increase in single L-type
calcium channels in hippocampal neurons during aging.
Science 272, 1017–1020.
242. Smith IF, Hitt B, Green KN, et al. (2005) Enhanced caffeine-
induced Ca2þ release in the 3xTg-AD mouse model of
Alzheimer’s disease. J Neurochem 94, 1711–1718.
243. Kopp-Hoolihan L (2001) Prophylactic and therapeutic uses
of probiotics: a review. J Am Diet Assoc 101, 229–241.
244. Butt H, Dunstan R & McGregor N, et al. (2001) Bacterial
colonosis in patients with persistent fatigue. In Proceedings
of the AHMF International Clinical and Scientific Confer-
ence, Sydney, Australia.
245. Logan A & Katzman M (2005) Major depressive disorder:
probiotics may be an adjuvant therapy. Med Hypotheses
64, 533–538.
246. Desbonnet L, Garrett L, Clarke G, et al. (2008) The probiotic
Bifidobacteria infantis: an assessment of potential anti-
depressant properties in the rat. J Psychiatr Res 43,
164–174.
247. Benton D, Williams C & Brown A (2007) Impact of consum-
ing a milk drink containing a probiotic on mood and cog-
nition. Eur J Clin Nutr 61, 355–361.
248. Lomer MCE, Parkes GC & Sanderson JD (2008) Review
Article: lactose intolerance in clinical practice – myths
and realities. Aliment Pharmacol Ther 27, 93–103.
D. A. Camfield et al.174
B
ri
ti
sh
Jo
u
rn
al
o
f
N
u
tr
it
io
n
